Drug Profile
JKB 122
Alternative Names: JKB-122Latest Information Update: 05 Sep 2023
Price :
$50
*
At a glance
- Originator Jenken Biosciences
- Developer Jenken Biosciences; TaiwanJ Pharmaceuticals
- Class Anti-inflammatories; Antifibrotics; Antivirals; Hepatoprotectants; Small molecules
- Mechanism of Action Immunomodulators; Toll-like receptor 4 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Autoimmune hepatitis; Crohn's disease; Hepatitis; Hepatitis C; Non-alcoholic fatty liver disease
- No development reported Non-alcoholic steatohepatitis
Most Recent Events
- 29 Aug 2023 Biostax Corp signs a research collaboration agreement with Immgenuity to focus on using JKB 122 and naltrexone with Immgenuity’s IMTV014 both independently and together to achieve remission with HIV patients
- 20 Aug 2023 Immune Therapeutics accepts transfer of three IND applications for Nonalcoholic steatohepatitis (NASH), fibrosis, Nonalcoholic Liver Disease (NAFLD) and Autoimmune Hepatitis along with the Orphan Designation for Autoimmune Hepatitis from TaiwanJ Pharmaceuticals
- 28 Jun 2023 No recent reports of development identified for preclinical development in Non-alcoholic-steatohepatitis in Taiwan (PO, Controlled release)